Computational drug repurposing: approaches, evaluation of in silico resources and case studies
- PMID: 40102635
- DOI: 10.1038/s41573-025-01164-x
Computational drug repurposing: approaches, evaluation of in silico resources and case studies
Abstract
Repurposing of existing drugs for new indications has attracted substantial attention owing to its potential to accelerate drug development and reduce costs. Hundreds of computational resources such as databases and predictive platforms have been developed that can be applied for drug repurposing, making it challenging to select the right resource for a specific drug repurposing project. With the aim of helping to address this challenge, here we overview computational approaches to drug repurposing based on a comprehensive survey of available in silico resources using a purpose-built drug repurposing ontology that classifies the resources into hierarchical categories and provides application-specific information. We also present an expert evaluation of selected resources and three drug repurposing case studies implemented within the Horizon Europe REMEDi4ALL project to demonstrate the practical use of the resources. This comprehensive Review with expert evaluations and case studies provides guidelines and recommendations on the best use of various in silico resources for drug repurposing and establishes a basis for a sustainable and extendable drug repurposing web catalogue.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: A.F.-T., I.G.G., R.G.-S., J.Q. and J.M. are employees of Chemotargets, a partner of the REMEDi4ALL project. ClarityVista is a software platform developed by Chemotargets. J.C.-P. and O.S. declare ownership in Phenaros Pharmaceuticals AB. T.C. and A.R.B. are employees of Dompé farmaceutici SpA, a partner of the REMEDi4ALL project. All the other authors declare no competing interests.
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
Image based subcellular mapping of the protein landscape of SARS-CoV-2 infected cells for target-centric drug repurposing.Biomed Pharmacother. 2025 Aug 16;191:118447. doi: 10.1016/j.biopha.2025.118447. Online ahead of print. Biomed Pharmacother. 2025. PMID: 40819539
Cited by
-
Uncovering the molecular targets of phytocannabinoids: mechanistic insights from inverse molecular docking fingerprint approaches.Front Pharmacol. 2025 Jun 27;16:1611461. doi: 10.3389/fphar.2025.1611461. eCollection 2025. Front Pharmacol. 2025. PMID: 40657640 Free PMC article.
References
-
- Batta, A., Kalra, B. S. & Khirasaria, R. Trends in FDA drug approvals over last 2 decades: an observational study. J. Fam. Med. Prim. Care 9, 105–114 (2020). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources